Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is headquartered in Redwood City, California.
IPO Year: 2021
Exchange: NASDAQ
Website: biomeafusion.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2025 | $7.00 | Overweight | Piper Sandler |
| 10/9/2024 | $128.00 | Buy | Edward Jones |
| 9/27/2024 | $18.00 | Neutral → Buy | Rodman & Renshaw |
| 9/27/2024 | $54.00 | Hold → Buy | Truist |
| 8/29/2024 | $25.00 | Overweight | CapitalOne |
| 6/11/2024 | Buy → Hold | Truist | |
| 6/7/2024 | $30.00 → $5.00 | Overweight → Equal Weight | Barclays |
| 4/2/2024 | $51.00 → $14.00 | Overweight → Neutral | JP Morgan |
| 2/6/2024 | $55.00 | Buy | Truist |
| 7/27/2023 | $41.00 | Sector Outperform | Scotiabank |
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)
4 - Biomea Fusion, Inc. (0001840439) (Issuer)